Page last updated: 2024-08-22

nsc 3852 and Acute Myelogenous Leukemia

nsc 3852 has been researched along with Acute Myelogenous Leukemia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bartels, M; Coffer, PJ; Egan, DA; Govers, AMAP; Lelieveld, D; Sonneveld, E; Wiggers, CRM; Zwaan, CM	1

Other Studies

1 other study(ies) available for nsc 3852 and Acute Myelogenous Leukemia

Article	Year
Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia. Pediatric blood & cancer, 2019, Volume: 66, Issue:8 Topics: Apoptosis; Cell Proliferation; Child; Down Syndrome; Drug Screening Assays, Antitumor; Epigenesis, Genetic; High-Throughput Screening Assays; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxyquinolines; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Leukemoid Reaction; Nitroso Compounds; Prognosis; Tumor Cells, Cultured	2019

Article

Year

Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.

Pediatric blood & cancer, 2019, Volume: 66, Issue:8

Topics: Apoptosis; Cell Proliferation; Child; Down Syndrome; Drug Screening Assays, Antitumor; Epigenesis, Genetic; High-Throughput Screening Assays; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxyquinolines; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Leukemoid Reaction; Nitroso Compounds; Prognosis; Tumor Cells, Cultured

2019